GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » LT-Debt-to-Total-Asset

ASEP Medical Holdings (ASEP Medical Holdings) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ASEP Medical Holdings's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

ASEP Medical Holdings's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).


ASEP Medical Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for ASEP Medical Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASEP Medical Holdings LT-Debt-to-Total-Asset Chart

ASEP Medical Holdings Annual Data
Trend Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
- - -

ASEP Medical Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ASEP Medical Holdings LT-Debt-to-Total-Asset Calculation

ASEP Medical Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/19.091
=0.00

ASEP Medical Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=0/18.641
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASEP Medical Holdings  (OTCPK:SEPSF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


ASEP Medical Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ASEP Medical Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


ASEP Medical Holdings (ASEP Medical Holdings) Business Description

Traded in Other Exchanges
Address
730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7
ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.